LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

LLY

916.49

-1.52%↓

JNJ

237.15

-0.37%↓

ABBV

208.28

-5.27%↓

NVS

149.76

-3.06%↓

AZN

188.42

-1.47%↓

Начало・Списък с акции・AbCellera Biologics Inc

AbCellera Biologics Inc

Затворен

СекторЗдравеопазване

3.51

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

3.44

Максимум

3.58

Ключови измерители
By Trading Economics
Приходи	48M -8.9M
Продажби	36M 45M
Марж на печалбата	-19.942
Служители	562
EBITDA	22M -18M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+97.18% upside

Дивиденти
By Dow Jones
Следващи печалби	7.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	172M 1.1B
Предишно отваряне	3.51
Предишно затваряне	3.51

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

1.99 / 2.635 Подкрепа & съпротива

AbCellera Biologics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

18.03.2026 г., 22:51 ч. UTC

Печалби

AIA Group Value of New Business Rose in 2025, Plans $1.7 Billion New Share Buyback

18.03.2026 г., 21:40 ч. UTC

Придобивния, сливания и поглъщания

Constellation Energy to Sell Portfolio of Assets for $5 Billion to Satisfy Regulators

18.03.2026 г., 20:31 ч. UTC

Печалби

Micron 2Q Sales Nearly Triple Amid Tight Memory Supply

18.03.2026 г., 23:49 ч. UTC

Пазарно говорене

Значими събития в новините

Nikkei May Fall on Renewed Concerns About Higher Energy Prices -- Market Talk

18.03.2026 г., 23:31 ч. UTC

Пазарно говорене

Gold Rises on Likely Technical Recovery -- Market Talk

18.03.2026 г., 22:49 ч. UTC

Пазарно говорене

New Zealand's Economic Recovery Has Yet to Find Footing -- Market Talk

18.03.2026 г., 22:41 ч. UTC

Пазарно говорене

Woodside Energy Opts for 'Safe, Experienced' Choice as CEO -- Market Talk

18.03.2026 г., 22:36 ч. UTC

Печалби

AIA Group Value of New Business Rose in 2025, Plans $1.7B New Share Buyback

18.03.2026 г., 22:24 ч. UTC

Печалби

AIA Group Announces New Share Buyback of $1.7B >1299.HK

18.03.2026 г., 22:23 ч. UTC

Печалби

AIA Group 2025 Value of New Business Margin Was 58.5%, Up 3.6 Ppt on Year >1299.HK

18.03.2026 г., 22:23 ч. UTC

Печалби

AIA Group 2025 Value of New Business $5.52B Vs. $4.71B >1299.HK

18.03.2026 г., 21:58 ч. UTC

Печалби

Micron Sales Nearly Triple Amid Tight Memory Supply -- Update

18.03.2026 г., 21:55 ч. UTC

Пазарно говорене

Печалби

Global Equities Roundup: Market Talk

18.03.2026 г., 21:55 ч. UTC

Пазарно говорене

Печалби

Micron's Phone, PC Business Could Shrink Due to Memory Shortage -- Market Talk

18.03.2026 г., 21:40 ч. UTC

Пазарно говорене

Fuel Price Rise Equates to 20 Bps Rate Hike on Australian Households -- Market Talk

18.03.2026 г., 21:16 ч. UTC

Пазарно говорене

More Procter & Gamble Alumni Join Strobel at Coty -- Market Talk

18.03.2026 г., 21:00 ч. UTC

Значими събития в новините

Iran War Puts Pressure on Japan's Economy. Takaichi Is In a Bind. -- Barrons.com

18.03.2026 г., 20:58 ч. UTC

Печалби

Micron 2Q Gross Margin Nearly Doubled Due to Higher Pricing, CFO Says

18.03.2026 г., 20:41 ч. UTC

Печалби

Micron Reports Extraordinary Earnings. Its Growth Is Accelerating. -- Barrons.com

18.03.2026 г., 20:29 ч. UTC

Печалби

Micron Reports Extraordinary Earnings. Its Growth Is Accelerating. -- Barrons.com

18.03.2026 г., 20:25 ч. UTC

Печалби

Micron Reports Extraordinary Earnings. Its Growth Is Accelerating. -- Barrons.com

18.03.2026 г., 20:17 ч. UTC

Печалби

These Stocks Are Today's Movers: Micron, Swarmer, Lumentum, Trade Desk, Macy's, Williams-Sonoma, and More -- Barrons.com

18.03.2026 г., 20:14 ч. UTC

Пазарно говорене

Airlines Can't Offset Higher Fuel Prices for Long -- Market Talk

18.03.2026 г., 20:09 ч. UTC

Печалби

Micron Reports Extraordinary Earnings. The Stock Is Up. -- Barrons.com

18.03.2026 г., 20:07 ч. UTC

Печалби

Micron Technology Raises Qtr Dividend to 15c Vs. 11.5c >MU

18.03.2026 г., 20:06 ч. UTC

Печалби

Micron Technology Board Has Approved 30% Increase in Qtrly Div >MU

18.03.2026 г., 20:04 ч. UTC

Печалби

Micron Technology 2Q Operating Cash Flow $11.9 B >MU

18.03.2026 г., 20:04 ч. UTC

Печалби

Micron Technology Sees 3Q Operating Expenses About $1.6 B >MU

18.03.2026 г., 20:04 ч. UTC

Печалби

Micron Technology Sees 3Q Gross Margin About 81% >MU

18.03.2026 г., 20:03 ч. UTC

Печалби

Micron Technology Sees 3Q Adj EPS $19.15 +/- 40c >MU

Сравнение с други в отрасъла

Ценова промяна

AbCellera Biologics Inc Прогноза

Ценова цел

By TipRanks

97.18% нагоре

12-месечна прогноза

Среден 7 USD 97.18%

Висок 7 USD

Нисък 7 USD

Според 4 анализатори от Wall Street, предложили 12-месечна ценова цел за AbCellera Biologics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

4 ratings

Купи

Задържане

Продай

Според 4 анализатори, дали борсови рейтинги на AbCellera Biologics Inc през последните 3 месеца.

Техническа оценка

By Trading Central

1.99 / 2.635Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно AbCellera Biologics Inc

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.